Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|June 1, 2022

The Mental Health Effects of Human Trafficking

Author(s)Lujain Alhajji, MD

Mental health clinicians should be more aware of how to identify and assist potential victims of human trafficking.

Lujain Alhajji, MD, discusses what patients are vulnerable to being trafficked and their barriers to care.

To read more about human trafficking, see our December 2021 CME article, Psychiatrists’ Response to Human Trafficking.

Dr Alhajji is an assistant professor in the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

psychiatry on trial

Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients’ Criminal Behavior?

ByFernando Espí Forcén, MD, PhD,Susan Hatters Friedman, MD, MSt, DFAPA

August 27th 2026

digital vs print

Digital Amnesia and Why Print Should Be Prized

ByRonald W. Pies, MD

August 21st 2026

trauma

Podcast: Navigating Trauma, Transformations, and Truth With Emily Lafferman, MD

ByFrank A. Clark, MD,Emily Lafferman, MD

August 5th 2026

AI brain

What Designing AI Taught Me About Why Psychiatrists Ignore It

ByCynthia Sin Nga Lam, MBBS, MRCPsych

July 28th 2026

1 expert is featured in this series.

Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy

ByDavid Walling, PhD

July 8th 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

Agitation Associated with Dementia Due to Alzheimer’s Disease: How Common Is It, and How Does It Present?

Podcast: Tips for Treating Sexual Dysfunction With Anita H. Clayton, MD

Differentiating Agitation from Depression, Anxiety, and Psychosis

Podcast: What Public Health Can Teach Us About Culturally Affirming Care